The drug semaglutide, sold under brand names Ozempic and Wegovy, can help reduce heart failure symptoms and reduce heart failure hospitalizations in patients with obesity, according to a pair of studies published in The New England Journal of Medicine.
Study participants who had obesity, HFpEF, and diabetes who received semaglutide lost more than double the weight of participants on placebo, were able to walk farther during a timed test, and saw a drop in heart failure and inflammation-related biomarkers.
[
add
]
[
|
|
...
]